Quantcast

Latest Nonbenzodiazepines Stories

2014-07-01 08:29:02

Merger to result in NASDAQ-listed biopharmaceutical company whose lead asset is a novel Phase 3-ready, oral and intravenous antibiotic drug candidate designed to address the treatment needs of patients with serious community-acquired bacterial infections. BOSTON, Mass., and POINT RICHMOND, Calif., July 1, 2014 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) and Paratek Pharmaceuticals, Inc., a privately-held biopharmaceutical company, announced today that they have entered into...

2014-05-20 23:14:29

On May 15, the FDA warned that Eszopiclone Containing Sleep Aids (including Lunesta and generics) can cause next-day impairment of driving and other activities that require alertness. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) May 20, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts...

2014-05-14 08:31:17

POINT RICHMOND, Calif., May 14, 2014 /PRNewswire/ -- Transcept Pharmaceuticals Inc. (NASDAQ: TSPT) announced today that its board of directors declared a special cash dividend of $1.33 per share on the Company's common stock. Payment will be made on June 3, 2014, to stockholders of record at the close of business on May 26, 2014. "We are pleased to distribute a significant amount of cash to our stockholders, and we continue to explore a range of alternatives to enhance stockholder...

2014-05-05 16:27:36

POINT RICHMOND, Calif., May 5, 2014 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three months ended March 31, 2014. Transcept reported cash, cash equivalents and marketable securities of $69.8 million at March 31, 2014. "We continue to explore a...

2014-04-15 12:29:59

PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.'s Lunesta(®). Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of insomnia. Eszopiclone Tablets 1 mg, 2 mg, 3 mg had U.S. sales of approximately $851.8...

2014-04-02 12:32:38

Both Surveyed Physicians and Payers are Sensitive to the Risk of Next-Day Impairment with Insomnia Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 2, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. and European psychiatrists ascribe the highest level of unmet need in insomnia treatment to be for new therapies with a reduced risk of abuse and tolerance. Several currently available insomnia therapies are designated as controlled...

2014-01-13 20:21:44

POINT RICHMOND, Calif., Jan. 13, 2014 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced the dismissal of the derivative lawsuit by the Court of Chancery of the State of Delaware. The derivative lawsuit was filed on October 24, 2013, by a shareholder, Retrophin Inc., against the Transcept Board of Directors, purporting to assert claims on behalf of Transcept, alleging that our Board of Directors approved and paid excessive compensation to our directors....


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related